RxDoctor Payments Data

James Brewer

Optometrist · Augusta, MENPI 1336403286

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Alcon at 38.2% of the total. 2025 is the largest year on record at $238, 2.3 times the $103 reported in 2019.

$1,069in general payments, 2019–2025

Across 49 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$409
  • Coopervision Inc.$201
  • AbbVie$117
  • Novartis$84
  • Johnson & Johnson Vision Care, Inc.$75
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$58
  • plus $126 from 5 others

What the payments were for

  • Food & beverage$1,069100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,069 in reported general payments places this provider in the 80th percentile of 224 optometrist providers in Maine.

See all optometrist providers in Maine

Medicare billing

Part B allowed, 2024
$32,336
Medicare patients
172
Services billed
1,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost61$38,905
RestasisCyclosporine21$35,882
XiidraLifitegrast14$10,901
SimbrinzaBrinzolamide/Brimonidine Tart23$6,803
Travoprost11$1,617
Latanoprost38$558
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$417
Timolol Maleate14$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$117$74,78782 claims
Bausch & Lomb Americas Inc.Xiidra$34$10,90114 claims
AlconSimbrinza$409$6,80323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 224 optometrist providers in Maine.

Other optometrist in Augusta

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →